nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—schizophrenia—Dimenhydrinate—atopic dermatitis	0.435	0.569	CpDpCtD
Lithium—schizophrenia—Diphenhydramine—atopic dermatitis	0.33	0.431	CpDpCtD
Lithium—IMPA2—skin of body—atopic dermatitis	0.00137	0.263	CbGeAlD
Lithium—IMPA1—head—atopic dermatitis	0.00119	0.229	CbGeAlD
Lithium—GRIA3—head—atopic dermatitis	0.00101	0.194	CbGeAlD
Lithium—GSK3B—head—atopic dermatitis	0.000875	0.168	CbGeAlD
Lithium—GSK3A—head—atopic dermatitis	0.000761	0.146	CbGeAlD
Lithium—IMPA1—Metabolism—ADSL—atopic dermatitis	0.0004	0.00455	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—CD79A—atopic dermatitis	0.000381	0.00434	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—MAPK8—atopic dermatitis	0.000377	0.00429	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—DEFB1—atopic dermatitis	0.000365	0.00416	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—NGF—atopic dermatitis	0.000361	0.00411	CbGpPWpGaD
Lithium—GSK3A—Unfolded Protein Response (UPR)—CXCL8—atopic dermatitis	0.000354	0.00403	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—IL1B—atopic dermatitis	0.00035	0.00399	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	0.000331	0.00377	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—NPS—atopic dermatitis	0.00033	0.00375	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—CASP8—atopic dermatitis	0.000327	0.00372	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FCER1A—atopic dermatitis	0.000326	0.00371	CbGpPWpGaD
Lithium—GSK3B—Signaling events mediated by Stem cell factor receptor (c-Kit)—MAPK8—atopic dermatitis	0.000323	0.00368	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—NFKBIA—atopic dermatitis	0.000321	0.00366	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—MAPK8—atopic dermatitis	0.000321	0.00365	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway Netpath—MAPK8—atopic dermatitis	0.000318	0.00362	CbGpPWpGaD
Lithium—GSK3B—Regulation of Androgen receptor activity—MAPK8—atopic dermatitis	0.000313	0.00356	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—MAPK8—atopic dermatitis	0.000309	0.00351	CbGpPWpGaD
Lithium—GSK3B—Role of Calcineurin-dependent NFAT signaling in lymphocytes—MAPK8—atopic dermatitis	0.000309	0.00351	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—NFKBIA—atopic dermatitis	0.000308	0.0035	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTSE—atopic dermatitis	0.000307	0.0035	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—BDNF—atopic dermatitis	0.000307	0.00349	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—CXCL8—atopic dermatitis	0.000306	0.00348	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—GLB1—atopic dermatitis	0.000305	0.00347	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—MAPK8—atopic dermatitis	0.000304	0.00346	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MS4A2—atopic dermatitis	0.000303	0.00345	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—TNF—atopic dermatitis	0.000299	0.0034	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—MAPK8—atopic dermatitis	0.000287	0.00327	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—CD79A—atopic dermatitis	0.000282	0.00321	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KIF3A—atopic dermatitis	0.000281	0.00319	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—NGF—atopic dermatitis	0.000277	0.00315	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—NGF—atopic dermatitis	0.000272	0.0031	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IFNG—atopic dermatitis	0.00027	0.00307	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—DEFB1—atopic dermatitis	0.00027	0.00307	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—atopic dermatitis	0.00027	0.00307	CbGpPWpGaD
Lithium—GRIA3—BDNF signaling pathway—MAPK8—atopic dermatitis	0.000266	0.00303	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—CASP8—atopic dermatitis	0.000264	0.003	CbGpPWpGaD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—MAPK8—atopic dermatitis	0.000261	0.00297	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—IL1B—atopic dermatitis	0.000259	0.00294	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—NFKBIA—atopic dermatitis	0.000257	0.00293	CbGpPWpGaD
Lithium—GSK3A—Immune System—FCER1A—atopic dermatitis	0.000257	0.00292	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—CXCL8—atopic dermatitis	0.000251	0.00286	CbGpPWpGaD
Lithium—GSK3B—CDC42 signaling events—MAPK8—atopic dermatitis	0.000251	0.00285	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—STAT6—atopic dermatitis	0.000248	0.00283	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—IL1B—atopic dermatitis	0.000248	0.00282	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	0.000242	0.00276	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CARD11—atopic dermatitis	0.000242	0.00275	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—IL6—atopic dermatitis	0.000241	0.00274	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—TNF—atopic dermatitis	0.000241	0.00274	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL2—atopic dermatitis	0.00024	0.00273	CbGpPWpGaD
Lithium—GSK3A—Immune System—MS4A2—atopic dermatitis	0.000239	0.00272	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—NFKBIA—atopic dermatitis	0.000238	0.00271	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—MAPK8—atopic dermatitis	0.000237	0.0027	CbGpPWpGaD
Lithium—GSK3B—IL-6 signaling pathway—IL6—atopic dermatitis	0.000236	0.00269	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CARD11—atopic dermatitis	0.000232	0.00264	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CMA1—atopic dermatitis	0.000231	0.00263	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—CXCL8—atopic dermatitis	0.000229	0.00261	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—NFKBIA—atopic dermatitis	0.000224	0.00255	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IFNG—atopic dermatitis	0.000222	0.00252	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—MAPK8—atopic dermatitis	0.000221	0.00251	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—IL2—atopic dermatitis	0.000219	0.00249	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	0.000219	0.00249	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—MAPK8—atopic dermatitis	0.000217	0.00247	CbGpPWpGaD
Lithium—GSK3A—Immune System—DEFB1—atopic dermatitis	0.000213	0.00242	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NGF—atopic dermatitis	0.000213	0.00242	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KIF3A—atopic dermatitis	0.000207	0.00236	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—CXCL8—atopic dermatitis	0.000206	0.00235	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NGF—atopic dermatitis	0.000204	0.00233	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—MAPK8—atopic dermatitis	0.000201	0.00229	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—atopic dermatitis	0.000199	0.00227	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL1B—atopic dermatitis	0.000198	0.00225	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—PPARA—atopic dermatitis	0.000194	0.00221	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—MAPK8—atopic dermatitis	0.000193	0.0022	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NFKBIA—atopic dermatitis	0.00019	0.00217	CbGpPWpGaD
Lithium—GSK3B—Immune System—FCER1A—atopic dermatitis	0.00019	0.00216	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CASP1—atopic dermatitis	0.000188	0.00214	CbGpPWpGaD
Lithium—GSK3A—Disease—GLB1—atopic dermatitis	0.000187	0.00213	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—STAT6—atopic dermatitis	0.000184	0.00209	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TNF—atopic dermatitis	0.00018	0.00205	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CARD11—atopic dermatitis	0.000179	0.00203	CbGpPWpGaD
Lithium—GSK3B—Immune System—MS4A2—atopic dermatitis	0.000176	0.00201	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—NFKBIA—atopic dermatitis	0.000176	0.002	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—MAPK8—atopic dermatitis	0.000176	0.002	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NFKBIA—atopic dermatitis	0.000175	0.002	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—MAPK8—atopic dermatitis	0.000175	0.00199	CbGpPWpGaD
Lithium—Dry skin—Dexamethasone—atopic dermatitis	0.000172	0.00121	CcSEcCtD
Lithium—Abdominal pain—Mometasone—atopic dermatitis	0.000172	0.00121	CcSEcCtD
Lithium—Body temperature increased—Mometasone—atopic dermatitis	0.000172	0.00121	CcSEcCtD
Lithium—Weight decreased—Hydrocortisone—atopic dermatitis	0.000172	0.0012	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CARD11—atopic dermatitis	0.000171	0.00195	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—atopic dermatitis	0.000171	0.00195	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TLR2—atopic dermatitis	0.00017	0.00194	CbGpPWpGaD
Lithium—GSK3A—Immune System—KIF3A—atopic dermatitis	0.00017	0.00194	CbGpPWpGaD
Lithium—Shock—Tacrolimus—atopic dermatitis	0.00017	0.00119	CcSEcCtD
Lithium—Dizziness—Loratadine—atopic dermatitis	0.000167	0.00118	CcSEcCtD
Lithium—Lethargy—Prednisone—atopic dermatitis	0.000167	0.00117	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—FCER2—atopic dermatitis	0.000166	0.00189	CbGpPWpGaD
Lithium—Muscular weakness—Betamethasone—atopic dermatitis	0.000165	0.00116	CcSEcCtD
Lithium—Muscular weakness—Dexamethasone—atopic dermatitis	0.000165	0.00116	CcSEcCtD
Lithium—Anorexia—Tacrolimus—atopic dermatitis	0.000165	0.00116	CcSEcCtD
Lithium—Weight increased—Triamcinolone—atopic dermatitis	0.000163	0.00114	CcSEcCtD
Lithium—Weight increased—Methylprednisolone—atopic dermatitis	0.000162	0.00114	CcSEcCtD
Lithium—Hypotension—Tacrolimus—atopic dermatitis	0.000162	0.00113	CcSEcCtD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	0.000162	0.00184	CbGpPWpGaD
Lithium—Vomiting—Loratadine—atopic dermatitis	0.000161	0.00113	CcSEcCtD
Lithium—Rash—Loratadine—atopic dermatitis	0.00016	0.00112	CcSEcCtD
Lithium—Dermatitis—Loratadine—atopic dermatitis	0.000159	0.00112	CcSEcCtD
Lithium—Headache—Loratadine—atopic dermatitis	0.000159	0.00111	CcSEcCtD
Lithium—Bradycardia—Prednisolone—atopic dermatitis	0.000158	0.00111	CcSEcCtD
Lithium—Musculoskeletal discomfort—Tacrolimus—atopic dermatitis	0.000158	0.00111	CcSEcCtD
Lithium—GSK3B—Immune System—DEFB1—atopic dermatitis	0.000157	0.00179	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NGF—atopic dermatitis	0.000157	0.00179	CbGpPWpGaD
Lithium—Asthenia—Mometasone—atopic dermatitis	0.000156	0.00109	CcSEcCtD
Lithium—Diarrhoea—Fluocinolone Acetonide—atopic dermatitis	0.000156	0.00109	CcSEcCtD
Lithium—Bradycardia—Hydrocortisone—atopic dermatitis	0.000155	0.00108	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CCL22—atopic dermatitis	0.000154	0.00176	CbGpPWpGaD
Lithium—Somnolence—Tacrolimus—atopic dermatitis	0.000154	0.00108	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CD79A—atopic dermatitis	0.000154	0.00175	CbGpPWpGaD
Lithium—Dyspepsia—Tacrolimus—atopic dermatitis	0.000152	0.00107	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	0.000152	0.00173	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PPARA—atopic dermatitis	0.000152	0.00173	CbGpPWpGaD
Lithium—Hallucination—Hydrocortisone—atopic dermatitis	0.000151	0.00106	CcSEcCtD
Lithium—Dizziness—Fluocinolone Acetonide—atopic dermatitis	0.00015	0.00106	CcSEcCtD
Lithium—Nausea—Loratadine—atopic dermatitis	0.00015	0.00106	CcSEcCtD
Lithium—Decreased appetite—Tacrolimus—atopic dermatitis	0.00015	0.00106	CcSEcCtD
Lithium—Dry skin—Prednisone—atopic dermatitis	0.00015	0.00105	CcSEcCtD
Lithium—Fatigue—Tacrolimus—atopic dermatitis	0.000149	0.00105	CcSEcCtD
Lithium—Diarrhoea—Mometasone—atopic dermatitis	0.000149	0.00104	CcSEcCtD
Lithium—Weight increased—Betamethasone—atopic dermatitis	0.000147	0.00104	CcSEcCtD
Lithium—Weight increased—Dexamethasone—atopic dermatitis	0.000147	0.00104	CcSEcCtD
Lithium—Weight decreased—Betamethasone—atopic dermatitis	0.000147	0.00103	CcSEcCtD
Lithium—Weight decreased—Dexamethasone—atopic dermatitis	0.000147	0.00103	CcSEcCtD
Lithium—Hyperglycaemia—Dexamethasone—atopic dermatitis	0.000146	0.00103	CcSEcCtD
Lithium—Hyperglycaemia—Betamethasone—atopic dermatitis	0.000146	0.00103	CcSEcCtD
Lithium—Bradycardia—Triamcinolone—atopic dermatitis	0.000146	0.00102	CcSEcCtD
Lithium—Bradycardia—Methylprednisolone—atopic dermatitis	0.000145	0.00102	CcSEcCtD
Lithium—GSK3A—Immune System—STAT6—atopic dermatitis	0.000145	0.00165	CbGpPWpGaD
Lithium—Vomiting—Fluocinolone Acetonide—atopic dermatitis	0.000145	0.00102	CcSEcCtD
Lithium—Muscular weakness—Prednisone—atopic dermatitis	0.000144	0.00101	CcSEcCtD
Lithium—Rash—Fluocinolone Acetonide—atopic dermatitis	0.000143	0.00101	CcSEcCtD
Lithium—Dermatitis—Fluocinolone Acetonide—atopic dermatitis	0.000143	0.00101	CcSEcCtD
Lithium—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000143	0.001	CcSEcCtD
Lithium—Feeling abnormal—Tacrolimus—atopic dermatitis	0.000142	0.001	CcSEcCtD
Lithium—Hallucination—Methylprednisolone—atopic dermatitis	0.000142	0.000996	CcSEcCtD
Lithium—Gastrointestinal pain—Tacrolimus—atopic dermatitis	0.000141	0.000993	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL6—atopic dermatitis	0.000141	0.00161	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—MAPK8—atopic dermatitis	0.000141	0.0016	CbGpPWpGaD
Lithium—GSK3A—Immune System—CARD11—atopic dermatitis	0.000141	0.0016	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CASP1—atopic dermatitis	0.000139	0.00158	CbGpPWpGaD
Lithium—Arrhythmia—Prednisolone—atopic dermatitis	0.000139	0.000975	CcSEcCtD
Lithium—GSK3B—Disease—GLB1—atopic dermatitis	0.000139	0.00158	CbGpPWpGaD
Lithium—Vomiting—Mometasone—atopic dermatitis	0.000138	0.00097	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CCL27—atopic dermatitis	0.000138	0.00157	CbGpPWpGaD
Lithium—Rash—Mometasone—atopic dermatitis	0.000137	0.000962	CcSEcCtD
Lithium—Dermatitis—Mometasone—atopic dermatitis	0.000137	0.000961	CcSEcCtD
Lithium—Body temperature increased—Tacrolimus—atopic dermatitis	0.000137	0.00096	CcSEcCtD
Lithium—Abdominal pain—Tacrolimus—atopic dermatitis	0.000137	0.00096	CcSEcCtD
Lithium—Headache—Mometasone—atopic dermatitis	0.000136	0.000955	CcSEcCtD
Lithium—Arrhythmia—Hydrocortisone—atopic dermatitis	0.000136	0.000952	CcSEcCtD
Lithium—IMPA1—Metabolism—PPARA—atopic dermatitis	0.000135	0.00154	CbGpPWpGaD
Lithium—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000135	0.000949	CcSEcCtD
Lithium—Bradycardia—Betamethasone—atopic dermatitis	0.000132	0.000927	CcSEcCtD
Lithium—Bradycardia—Dexamethasone—atopic dermatitis	0.000132	0.000927	CcSEcCtD
Lithium—Erectile dysfunction—Prednisone—atopic dermatitis	0.00013	0.000912	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NFKBIA—atopic dermatitis	0.00013	0.00148	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—MAPK8—atopic dermatitis	0.000129	0.00147	CbGpPWpGaD
Lithium—Hallucination—Dexamethasone—atopic dermatitis	0.000129	0.000906	CcSEcCtD
Lithium—Hallucination—Betamethasone—atopic dermatitis	0.000129	0.000906	CcSEcCtD
Lithium—Nausea—Mometasone—atopic dermatitis	0.000129	0.000906	CcSEcCtD
Lithium—Weight increased—Prednisone—atopic dermatitis	0.000128	0.000902	CcSEcCtD
Lithium—Arrhythmia—Triamcinolone—atopic dermatitis	0.000128	0.000896	CcSEcCtD
Lithium—Weight decreased—Prednisone—atopic dermatitis	0.000128	0.000896	CcSEcCtD
Lithium—Vision blurred—Prednisolone—atopic dermatitis	0.000128	0.000895	CcSEcCtD
Lithium—Arrhythmia—Methylprednisolone—atopic dermatitis	0.000127	0.000895	CcSEcCtD
Lithium—Hyperglycaemia—Prednisone—atopic dermatitis	0.000127	0.000894	CcSEcCtD
Lithium—GSK3B—Innate Immune System—TLR2—atopic dermatitis	0.000126	0.00143	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIF3A—atopic dermatitis	0.000126	0.00143	CbGpPWpGaD
Lithium—GSK3A—Disease—SLC11A1—atopic dermatitis	0.000126	0.00143	CbGpPWpGaD
Lithium—Asthenia—Tacrolimus—atopic dermatitis	0.000124	0.000871	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CD8A—atopic dermatitis	0.000124	0.00141	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—IL6—atopic dermatitis	0.000124	0.00141	CbGpPWpGaD
Lithium—Angioedema—Prednisolone—atopic dermatitis	0.000124	0.000868	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CCL17—atopic dermatitis	0.000123	0.0014	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FCER2—atopic dermatitis	0.000123	0.0014	CbGpPWpGaD
Lithium—Dysgeusia—Triamcinolone—atopic dermatitis	0.000122	0.000855	CcSEcCtD
Lithium—Vertigo—Prednisolone—atopic dermatitis	0.000122	0.000853	CcSEcCtD
Lithium—Syncope—Prednisolone—atopic dermatitis	0.000121	0.000852	CcSEcCtD
Lithium—Angioedema—Hydrocortisone—atopic dermatitis	0.000121	0.000848	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	0.00012	0.00137	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	0.000119	0.00136	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisolone—atopic dermatitis	0.000119	0.000835	CcSEcCtD
Lithium—Vertigo—Hydrocortisone—atopic dermatitis	0.000119	0.000834	CcSEcCtD
Lithium—Syncope—Hydrocortisone—atopic dermatitis	0.000119	0.000832	CcSEcCtD
Lithium—GSK3A—Downstream signaling of activated FGFR—IL6—atopic dermatitis	0.000118	0.00135	CbGpPWpGaD
Lithium—Diarrhoea—Tacrolimus—atopic dermatitis	0.000118	0.00083	CcSEcCtD
Lithium—Convulsion—Prednisolone—atopic dermatitis	0.000117	0.000823	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB4—IL6—atopic dermatitis	0.000117	0.00133	CbGpPWpGaD
Lithium—Loss of consciousness—Hydrocortisone—atopic dermatitis	0.000116	0.000815	CcSEcCtD
Lithium—Arrhythmia—Dexamethasone—atopic dermatitis	0.000116	0.000813	CcSEcCtD
Lithium—Arrhythmia—Betamethasone—atopic dermatitis	0.000116	0.000813	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	0.000116	0.00132	CbGpPWpGaD
Lithium—Bradycardia—Prednisone—atopic dermatitis	0.000115	0.000807	CcSEcCtD
Lithium—Alopecia—Betamethasone—atopic dermatitis	0.000115	0.000805	CcSEcCtD
Lithium—Alopecia—Dexamethasone—atopic dermatitis	0.000115	0.000805	CcSEcCtD
Lithium—Convulsion—Hydrocortisone—atopic dermatitis	0.000115	0.000804	CcSEcCtD
Lithium—Dizziness—Tacrolimus—atopic dermatitis	0.000114	0.000803	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CCL22—atopic dermatitis	0.000114	0.0013	CbGpPWpGaD
Lithium—Discomfort—Prednisolone—atopic dermatitis	0.000114	0.000799	CcSEcCtD
Lithium—Angioedema—Triamcinolone—atopic dermatitis	0.000114	0.000798	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD79A—atopic dermatitis	0.000114	0.00129	CbGpPWpGaD
Lithium—Angioedema—Methylprednisolone—atopic dermatitis	0.000113	0.000796	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—MAPK8—atopic dermatitis	0.000113	0.00128	CbGpPWpGaD
Lithium—Hallucination—Prednisone—atopic dermatitis	0.000112	0.000789	CcSEcCtD
Lithium—Vertigo—Triamcinolone—atopic dermatitis	0.000112	0.000785	CcSEcCtD
Lithium—Syncope—Triamcinolone—atopic dermatitis	0.000112	0.000783	CcSEcCtD
Lithium—Vertigo—Methylprednisolone—atopic dermatitis	0.000112	0.000783	CcSEcCtD
Lithium—Syncope—Methylprednisolone—atopic dermatitis	0.000111	0.000782	CcSEcCtD
Lithium—GSK3A—Downstream signal transduction—IL6—atopic dermatitis	0.000111	0.00127	CbGpPWpGaD
Lithium—Discomfort—Hydrocortisone—atopic dermatitis	0.000111	0.00078	CcSEcCtD
Lithium—GSK3A—Signaling by FGFR—IL6—atopic dermatitis	0.000111	0.00126	CbGpPWpGaD
Lithium—Oedema—Prednisolone—atopic dermatitis	0.00011	0.000775	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB2—IL6—atopic dermatitis	0.00011	0.00125	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—MAPK8—atopic dermatitis	0.00011	0.00125	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIF3A—atopic dermatitis	0.00011	0.00125	CbGpPWpGaD
Lithium—Vomiting—Tacrolimus—atopic dermatitis	0.00011	0.000772	CcSEcCtD
Lithium—GSK3A—Immune System—CASP1—atopic dermatitis	0.00011	0.00125	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—IL6—atopic dermatitis	0.00011	0.00125	CbGpPWpGaD
Lithium—Loss of consciousness—Triamcinolone—atopic dermatitis	0.000109	0.000768	CcSEcCtD
Lithium—Loss of consciousness—Methylprednisolone—atopic dermatitis	0.000109	0.000766	CcSEcCtD
Lithium—Rash—Tacrolimus—atopic dermatitis	0.000109	0.000765	CcSEcCtD
Lithium—Dermatitis—Tacrolimus—atopic dermatitis	0.000109	0.000765	CcSEcCtD
Lithium—Shock—Prednisolone—atopic dermatitis	0.000109	0.000763	CcSEcCtD
Lithium—Headache—Tacrolimus—atopic dermatitis	0.000108	0.00076	CcSEcCtD
Lithium—Oedema—Hydrocortisone—atopic dermatitis	0.000108	0.000757	CcSEcCtD
Lithium—Convulsion—Triamcinolone—atopic dermatitis	0.000108	0.000757	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—MAPK8—atopic dermatitis	0.000108	0.00123	CbGpPWpGaD
Lithium—Convulsion—Methylprednisolone—atopic dermatitis	0.000108	0.000755	CcSEcCtD
Lithium—GSK3B—Immune System—STAT6—atopic dermatitis	0.000107	0.00122	CbGpPWpGaD
Lithium—Shock—Hydrocortisone—atopic dermatitis	0.000106	0.000745	CcSEcCtD
Lithium—Arthralgia—Methylprednisolone—atopic dermatitis	0.000106	0.000742	CcSEcCtD
Lithium—Discomfort—Triamcinolone—atopic dermatitis	0.000105	0.000735	CcSEcCtD
Lithium—Discomfort—Methylprednisolone—atopic dermatitis	0.000104	0.000733	CcSEcCtD
Lithium—GSK3B—Immune System—CARD11—atopic dermatitis	0.000104	0.00118	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL5—atopic dermatitis	0.000104	0.00118	CbGpPWpGaD
Lithium—Dry mouth—Triamcinolone—atopic dermatitis	0.000104	0.000727	CcSEcCtD
Lithium—Angioedema—Betamethasone—atopic dermatitis	0.000103	0.000724	CcSEcCtD
Lithium—Angioedema—Dexamethasone—atopic dermatitis	0.000103	0.000724	CcSEcCtD
Lithium—GSK3A—DAP12 interactions—IL6—atopic dermatitis	0.000103	0.00117	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	0.000103	0.00117	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—IL6—atopic dermatitis	0.000103	0.00117	CbGpPWpGaD
Lithium—Anorexia—Hydrocortisone—atopic dermatitis	0.000103	0.000722	CcSEcCtD
Lithium—Nausea—Tacrolimus—atopic dermatitis	0.000103	0.000721	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—IL6—atopic dermatitis	0.000102	0.00116	CbGpPWpGaD
Lithium—Confusional state—Methylprednisolone—atopic dermatitis	0.000102	0.000717	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CCL27—atopic dermatitis	0.000102	0.00116	CbGpPWpGaD
Lithium—Oedema—Triamcinolone—atopic dermatitis	0.000102	0.000713	CcSEcCtD
Lithium—Vertigo—Dexamethasone—atopic dermatitis	0.000101	0.000712	CcSEcCtD
Lithium—Vertigo—Betamethasone—atopic dermatitis	0.000101	0.000712	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR in Cancer—IL6—atopic dermatitis	0.000101	0.00115	CbGpPWpGaD
Lithium—Syncope—Dexamethasone—atopic dermatitis	0.000101	0.000711	CcSEcCtD
Lithium—Syncope—Betamethasone—atopic dermatitis	0.000101	0.000711	CcSEcCtD
Lithium—Arrhythmia—Prednisone—atopic dermatitis	0.000101	0.000708	CcSEcCtD
Lithium—GSK3A—Signaling by PDGF—IL6—atopic dermatitis	0.000101	0.00115	CbGpPWpGaD
Lithium—Hypotension—Hydrocortisone—atopic dermatitis	0.000101	0.000708	CcSEcCtD
Lithium—GSK3A—Innate Immune System—NFKBIA—atopic dermatitis	0.0001	0.00114	CbGpPWpGaD
Lithium—Shock—Triamcinolone—atopic dermatitis	9.99e-05	0.000701	CcSEcCtD
Lithium—Alopecia—Prednisone—atopic dermatitis	9.98e-05	0.000701	CcSEcCtD
Lithium—Shock—Methylprednisolone—atopic dermatitis	9.97e-05	0.0007	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CCL11—atopic dermatitis	9.95e-05	0.00113	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CMA1—atopic dermatitis	9.95e-05	0.00113	CbGpPWpGaD
Lithium—Loss of consciousness—Betamethasone—atopic dermatitis	9.92e-05	0.000697	CcSEcCtD
Lithium—Loss of consciousness—Dexamethasone—atopic dermatitis	9.92e-05	0.000697	CcSEcCtD
Lithium—GSK3A—Immune System—TLR2—atopic dermatitis	9.92e-05	0.00113	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CXCL8—atopic dermatitis	9.85e-05	0.00112	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	9.83e-05	0.00069	CcSEcCtD
Lithium—Convulsion—Betamethasone—atopic dermatitis	9.78e-05	0.000687	CcSEcCtD
Lithium—Convulsion—Dexamethasone—atopic dermatitis	9.78e-05	0.000687	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—NFKBIA—atopic dermatitis	9.61e-05	0.00109	CbGpPWpGaD
Lithium—Discomfort—Betamethasone—atopic dermatitis	9.5e-05	0.000667	CcSEcCtD
Lithium—Discomfort—Dexamethasone—atopic dermatitis	9.5e-05	0.000667	CcSEcCtD
Lithium—Dyspepsia—Hydrocortisone—atopic dermatitis	9.5e-05	0.000667	CcSEcCtD
Lithium—Hypotension—Methylprednisolone—atopic dermatitis	9.47e-05	0.000665	CcSEcCtD
Lithium—GSK3B—Developmental Biology—PPARA—atopic dermatitis	9.47e-05	0.00108	CbGpPWpGaD
Lithium—Decreased appetite—Hydrocortisone—atopic dermatitis	9.38e-05	0.000658	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—STAT6—atopic dermatitis	9.35e-05	0.00106	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD79A—atopic dermatitis	9.32e-05	0.00106	CbGpPWpGaD
Lithium—Fatigue—Hydrocortisone—atopic dermatitis	9.3e-05	0.000653	CcSEcCtD
Lithium—GSK3B—Disease—SLC11A1—atopic dermatitis	9.28e-05	0.00106	CbGpPWpGaD
Lithium—Vision blurred—Prednisone—atopic dermatitis	9.27e-05	0.000651	CcSEcCtD
Lithium—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	9.25e-05	0.00065	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	9.23e-05	0.000648	CcSEcCtD
Lithium—Oedema—Betamethasone—atopic dermatitis	9.22e-05	0.000647	CcSEcCtD
Lithium—Oedema—Dexamethasone—atopic dermatitis	9.22e-05	0.000647	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD8A—atopic dermatitis	9.16e-05	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—IL6—atopic dermatitis	9.14e-05	0.00104	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	9.14e-05	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL17—atopic dermatitis	9.12e-05	0.00104	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisolone—atopic dermatitis	9.1e-05	0.000639	CcSEcCtD
Lithium—Shock—Dexamethasone—atopic dermatitis	9.07e-05	0.000636	CcSEcCtD
Lithium—Shock—Betamethasone—atopic dermatitis	9.07e-05	0.000636	CcSEcCtD
Lithium—Agitation—Prednisone—atopic dermatitis	9.04e-05	0.000634	CcSEcCtD
Lithium—GSK3A—Innate Immune System—CASP8—atopic dermatitis	9.02e-05	0.00103	CbGpPWpGaD
Lithium—Angioedema—Prednisone—atopic dermatitis	8.99e-05	0.000631	CcSEcCtD
Lithium—Dyspepsia—Triamcinolone—atopic dermatitis	8.94e-05	0.000628	CcSEcCtD
Lithium—Dyspepsia—Methylprednisolone—atopic dermatitis	8.92e-05	0.000626	CcSEcCtD
Lithium—Feeling abnormal—Hydrocortisone—atopic dermatitis	8.89e-05	0.000624	CcSEcCtD
Lithium—Vertigo—Prednisone—atopic dermatitis	8.84e-05	0.00062	CcSEcCtD
Lithium—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	8.82e-05	0.000619	CcSEcCtD
Lithium—Syncope—Prednisone—atopic dermatitis	8.82e-05	0.000619	CcSEcCtD
Lithium—Anorexia—Dexamethasone—atopic dermatitis	8.78e-05	0.000617	CcSEcCtD
Lithium—Anorexia—Betamethasone—atopic dermatitis	8.78e-05	0.000617	CcSEcCtD
Lithium—Fatigue—Triamcinolone—atopic dermatitis	8.76e-05	0.000615	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—IL6—atopic dermatitis	8.75e-05	0.000996	CbGpPWpGaD
Lithium—Fatigue—Methylprednisolone—atopic dermatitis	8.74e-05	0.000613	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—MAPK8—atopic dermatitis	8.67e-05	0.000987	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisone—atopic dermatitis	8.64e-05	0.000607	CcSEcCtD
Lithium—Hypotension—Betamethasone—atopic dermatitis	8.61e-05	0.000604	CcSEcCtD
Lithium—Hypotension—Dexamethasone—atopic dermatitis	8.61e-05	0.000604	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—IL6—atopic dermatitis	8.61e-05	0.00098	CbGpPWpGaD
Lithium—Body temperature increased—Hydrocortisone—atopic dermatitis	8.53e-05	0.000599	CcSEcCtD
Lithium—Abdominal pain—Hydrocortisone—atopic dermatitis	8.53e-05	0.000599	CcSEcCtD
Lithium—Convulsion—Prednisone—atopic dermatitis	8.52e-05	0.000598	CcSEcCtD
Lithium—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	8.4e-05	0.000589	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	8.4e-05	0.000589	CcSEcCtD
Lithium—Arthralgia—Prednisone—atopic dermatitis	8.37e-05	0.000588	CcSEcCtD
Lithium—Feeling abnormal—Triamcinolone—atopic dermatitis	8.37e-05	0.000588	CcSEcCtD
Lithium—Feeling abnormal—Methylprednisolone—atopic dermatitis	8.35e-05	0.000586	CcSEcCtD
Lithium—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	8.29e-05	0.000582	CcSEcCtD
Lithium—Discomfort—Prednisone—atopic dermatitis	8.27e-05	0.000581	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—IL6—atopic dermatitis	8.22e-05	0.000936	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—IL6—atopic dermatitis	8.18e-05	0.000931	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—IL6—atopic dermatitis	8.14e-05	0.000927	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MAPK8—atopic dermatitis	8.13e-05	0.000925	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIF3A—atopic dermatitis	8.13e-05	0.000925	CbGpPWpGaD
Lithium—Dyspepsia—Dexamethasone—atopic dermatitis	8.11e-05	0.000569	CcSEcCtD
Lithium—Dyspepsia—Betamethasone—atopic dermatitis	8.11e-05	0.000569	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CCR3—atopic dermatitis	8.11e-05	0.000923	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP1—atopic dermatitis	8.1e-05	0.000922	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—IL6—atopic dermatitis	8.1e-05	0.000922	CbGpPWpGaD
Lithium—Body temperature increased—Triamcinolone—atopic dermatitis	8.03e-05	0.000564	CcSEcCtD
Lithium—Oedema—Prednisone—atopic dermatitis	8.03e-05	0.000563	CcSEcCtD
Lithium—Abdominal pain—Methylprednisolone—atopic dermatitis	8.01e-05	0.000562	CcSEcCtD
Lithium—Decreased appetite—Dexamethasone—atopic dermatitis	8.01e-05	0.000562	CcSEcCtD
Lithium—Decreased appetite—Betamethasone—atopic dermatitis	8.01e-05	0.000562	CcSEcCtD
Lithium—Fatigue—Dexamethasone—atopic dermatitis	7.95e-05	0.000558	CcSEcCtD
Lithium—Fatigue—Betamethasone—atopic dermatitis	7.95e-05	0.000558	CcSEcCtD
Lithium—Shock—Prednisone—atopic dermatitis	7.9e-05	0.000554	CcSEcCtD
Lithium—Asthenia—Hydrocortisone—atopic dermatitis	7.74e-05	0.000543	CcSEcCtD
Lithium—GSK3B—Immune System—IL5—atopic dermatitis	7.68e-05	0.000874	CbGpPWpGaD
Lithium—Anorexia—Prednisone—atopic dermatitis	7.65e-05	0.000537	CcSEcCtD
Lithium—GSK3A—Immune System—IL18—atopic dermatitis	7.63e-05	0.000868	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	7.62e-05	0.000868	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—atopic dermatitis	7.62e-05	0.000868	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—IL6—atopic dermatitis	7.62e-05	0.000868	CbGpPWpGaD
Lithium—Feeling abnormal—Betamethasone—atopic dermatitis	7.59e-05	0.000533	CcSEcCtD
Lithium—Feeling abnormal—Dexamethasone—atopic dermatitis	7.59e-05	0.000533	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—IL6—atopic dermatitis	7.55e-05	0.00086	CbGpPWpGaD
Lithium—Gastrointestinal pain—Betamethasone—atopic dermatitis	7.54e-05	0.000529	CcSEcCtD
Lithium—Gastrointestinal pain—Dexamethasone—atopic dermatitis	7.54e-05	0.000529	CcSEcCtD
Lithium—GSK3A—Immune System—CD8A—atopic dermatitis	7.51e-05	0.000855	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—atopic dermatitis	7.49e-05	0.000852	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—IL6—atopic dermatitis	7.45e-05	0.000848	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD4—atopic dermatitis	7.41e-05	0.000843	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NFKBIA—atopic dermatitis	7.39e-05	0.000841	CbGpPWpGaD
Lithium—Diarrhoea—Hydrocortisone—atopic dermatitis	7.38e-05	0.000518	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CMA1—atopic dermatitis	7.35e-05	0.000837	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL11—atopic dermatitis	7.35e-05	0.000837	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR2—atopic dermatitis	7.33e-05	0.000834	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Prednisone—atopic dermatitis	7.31e-05	0.000513	CcSEcCtD
Lithium—Dizziness—Prednisolone—atopic dermatitis	7.3e-05	0.000513	CcSEcCtD
Lithium—Asthenia—Triamcinolone—atopic dermatitis	7.29e-05	0.000512	CcSEcCtD
Lithium—Abdominal pain—Betamethasone—atopic dermatitis	7.29e-05	0.000511	CcSEcCtD
Lithium—Abdominal pain—Dexamethasone—atopic dermatitis	7.29e-05	0.000511	CcSEcCtD
Lithium—Body temperature increased—Betamethasone—atopic dermatitis	7.29e-05	0.000511	CcSEcCtD
Lithium—Body temperature increased—Dexamethasone—atopic dermatitis	7.29e-05	0.000511	CcSEcCtD
Lithium—Asthenia—Methylprednisolone—atopic dermatitis	7.27e-05	0.00051	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—NPS—atopic dermatitis	7.23e-05	0.000823	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TAC1—atopic dermatitis	7.23e-05	0.000823	CbGpPWpGaD
Lithium—Dizziness—Hydrocortisone—atopic dermatitis	7.13e-05	0.000501	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CD4—atopic dermatitis	7.12e-05	0.00081	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NFKBIA—atopic dermatitis	7.1e-05	0.000808	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCR3—atopic dermatitis	7.09e-05	0.000807	CbGpPWpGaD
Lithium—Dyspepsia—Prednisone—atopic dermatitis	7.06e-05	0.000496	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—IL6—atopic dermatitis	7.03e-05	0.0008	CbGpPWpGaD
Lithium—Decreased appetite—Prednisone—atopic dermatitis	6.98e-05	0.00049	CcSEcCtD
Lithium—Rash—Prednisolone—atopic dermatitis	6.96e-05	0.000489	CcSEcCtD
Lithium—Dermatitis—Prednisolone—atopic dermatitis	6.96e-05	0.000488	CcSEcCtD
Lithium—Diarrhoea—Methylprednisolone—atopic dermatitis	6.93e-05	0.000487	CcSEcCtD
Lithium—Fatigue—Prednisone—atopic dermatitis	6.92e-05	0.000486	CcSEcCtD
Lithium—Headache—Prednisolone—atopic dermatitis	6.92e-05	0.000486	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—STAT6—atopic dermatitis	6.91e-05	0.000787	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD79A—atopic dermatitis	6.89e-05	0.000784	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—atopic dermatitis	6.88e-05	0.000784	CbGpPWpGaD
Lithium—Vomiting—Hydrocortisone—atopic dermatitis	6.86e-05	0.000481	CcSEcCtD
Lithium—Rash—Hydrocortisone—atopic dermatitis	6.8e-05	0.000477	CcSEcCtD
Lithium—Dermatitis—Hydrocortisone—atopic dermatitis	6.79e-05	0.000477	CcSEcCtD
Lithium—Headache—Hydrocortisone—atopic dermatitis	6.76e-05	0.000474	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	6.75e-05	0.000768	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL5—atopic dermatitis	6.72e-05	0.000765	CbGpPWpGaD
Lithium—Dizziness—Triamcinolone—atopic dermatitis	6.72e-05	0.000471	CcSEcCtD
Lithium—Dizziness—Methylprednisolone—atopic dermatitis	6.7e-05	0.00047	CcSEcCtD
Lithium—GSK3B—Innate Immune System—CASP8—atopic dermatitis	6.67e-05	0.000759	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisone—atopic dermatitis	6.61e-05	0.000464	CcSEcCtD
Lithium—Asthenia—Dexamethasone—atopic dermatitis	6.61e-05	0.000464	CcSEcCtD
Lithium—Asthenia—Betamethasone—atopic dermatitis	6.61e-05	0.000464	CcSEcCtD
Lithium—Gastrointestinal pain—Prednisone—atopic dermatitis	6.56e-05	0.000461	CcSEcCtD
Lithium—Nausea—Prednisolone—atopic dermatitis	6.56e-05	0.000461	CcSEcCtD
Lithium—Vomiting—Triamcinolone—atopic dermatitis	6.46e-05	0.000453	CcSEcCtD
Lithium—Vomiting—Methylprednisolone—atopic dermatitis	6.44e-05	0.000452	CcSEcCtD
Lithium—Nausea—Hydrocortisone—atopic dermatitis	6.41e-05	0.00045	CcSEcCtD
Lithium—Rash—Triamcinolone—atopic dermatitis	6.4e-05	0.00045	CcSEcCtD
Lithium—Dermatitis—Triamcinolone—atopic dermatitis	6.4e-05	0.000449	CcSEcCtD
Lithium—Rash—Methylprednisolone—atopic dermatitis	6.39e-05	0.000449	CcSEcCtD
Lithium—Dermatitis—Methylprednisolone—atopic dermatitis	6.38e-05	0.000448	CcSEcCtD
Lithium—Headache—Triamcinolone—atopic dermatitis	6.36e-05	0.000447	CcSEcCtD
Lithium—Headache—Methylprednisolone—atopic dermatitis	6.35e-05	0.000446	CcSEcCtD
Lithium—GSK3A—Disease—CCR5—atopic dermatitis	6.35e-05	0.000722	CbGpPWpGaD
Lithium—Body temperature increased—Prednisone—atopic dermatitis	6.34e-05	0.000445	CcSEcCtD
Lithium—Abdominal pain—Prednisone—atopic dermatitis	6.34e-05	0.000445	CcSEcCtD
Lithium—Diarrhoea—Dexamethasone—atopic dermatitis	6.31e-05	0.000443	CcSEcCtD
Lithium—Diarrhoea—Betamethasone—atopic dermatitis	6.31e-05	0.000443	CcSEcCtD
Lithium—GSK3A—Innate Immune System—MAPK8—atopic dermatitis	6.28e-05	0.000714	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—atopic dermatitis	6.23e-05	0.00071	CbGpPWpGaD
Lithium—Dizziness—Betamethasone—atopic dermatitis	6.09e-05	0.000428	CcSEcCtD
Lithium—Dizziness—Dexamethasone—atopic dermatitis	6.09e-05	0.000428	CcSEcCtD
Lithium—Nausea—Triamcinolone—atopic dermatitis	6.03e-05	0.000423	CcSEcCtD
Lithium—Nausea—Methylprednisolone—atopic dermatitis	6.02e-05	0.000423	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CCR3—atopic dermatitis	5.99e-05	0.000682	CbGpPWpGaD
Lithium—Vomiting—Dexamethasone—atopic dermatitis	5.86e-05	0.000411	CcSEcCtD
Lithium—Vomiting—Betamethasone—atopic dermatitis	5.86e-05	0.000411	CcSEcCtD
Lithium—GSK3A—Immune System—NFKBIA—atopic dermatitis	5.83e-05	0.000663	CbGpPWpGaD
Lithium—Rash—Dexamethasone—atopic dermatitis	5.81e-05	0.000408	CcSEcCtD
Lithium—Rash—Betamethasone—atopic dermatitis	5.81e-05	0.000408	CcSEcCtD
Lithium—Dermatitis—Dexamethasone—atopic dermatitis	5.81e-05	0.000408	CcSEcCtD
Lithium—Dermatitis—Betamethasone—atopic dermatitis	5.81e-05	0.000408	CcSEcCtD
Lithium—Headache—Dexamethasone—atopic dermatitis	5.77e-05	0.000405	CcSEcCtD
Lithium—Headache—Betamethasone—atopic dermatitis	5.77e-05	0.000405	CcSEcCtD
Lithium—Asthenia—Prednisone—atopic dermatitis	5.76e-05	0.000404	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CXCL10—atopic dermatitis	5.73e-05	0.000652	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL18—atopic dermatitis	5.64e-05	0.000642	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—atopic dermatitis	5.55e-05	0.000632	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—atopic dermatitis	5.54e-05	0.00063	CbGpPWpGaD
Lithium—Diarrhoea—Prednisone—atopic dermatitis	5.49e-05	0.000385	CcSEcCtD
Lithium—GSK3B—Innate Immune System—CD4—atopic dermatitis	5.48e-05	0.000623	CbGpPWpGaD
Lithium—Nausea—Betamethasone—atopic dermatitis	5.47e-05	0.000384	CcSEcCtD
Lithium—Nausea—Dexamethasone—atopic dermatitis	5.47e-05	0.000384	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—TAC1—atopic dermatitis	5.34e-05	0.000608	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NPS—atopic dermatitis	5.34e-05	0.000608	CbGpPWpGaD
Lithium—Dizziness—Prednisone—atopic dermatitis	5.31e-05	0.000373	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD4—atopic dermatitis	5.26e-05	0.000599	CbGpPWpGaD
Lithium—GSK3A—Immune System—CASP8—atopic dermatitis	5.26e-05	0.000598	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCR3—atopic dermatitis	5.24e-05	0.000596	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—atopic dermatitis	5.19e-05	0.000591	CbGpPWpGaD
Lithium—Vomiting—Prednisone—atopic dermatitis	5.1e-05	0.000358	CcSEcCtD
Lithium—Rash—Prednisone—atopic dermatitis	5.06e-05	0.000355	CcSEcCtD
Lithium—Dermatitis—Prednisone—atopic dermatitis	5.06e-05	0.000355	CcSEcCtD
Lithium—Headache—Prednisone—atopic dermatitis	5.03e-05	0.000353	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—IL5—atopic dermatitis	4.97e-05	0.000565	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL5—atopic dermatitis	4.93e-05	0.000561	CbGpPWpGaD
Lithium—Nausea—Prednisone—atopic dermatitis	4.77e-05	0.000335	CcSEcCtD
Lithium—GSK3B—Axon guidance—IL6—atopic dermatitis	4.7e-05	0.000535	CbGpPWpGaD
Lithium—GSK3B—Disease—CCR5—atopic dermatitis	4.69e-05	0.000534	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK8—atopic dermatitis	4.64e-05	0.000528	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NGF—atopic dermatitis	4.57e-05	0.00052	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNG—atopic dermatitis	4.47e-05	0.000509	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCR5—atopic dermatitis	4.44e-05	0.000506	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—atopic dermatitis	4.32e-05	0.000491	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKBIA—atopic dermatitis	4.31e-05	0.00049	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL10—atopic dermatitis	4.23e-05	0.000482	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—atopic dermatitis	4.16e-05	0.000473	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—atopic dermatitis	4.01e-05	0.000456	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—atopic dermatitis	3.99e-05	0.000454	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—atopic dermatitis	3.98e-05	0.000454	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—atopic dermatitis	3.97e-05	0.000452	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP8—atopic dermatitis	3.88e-05	0.000442	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NFKBIA—atopic dermatitis	3.77e-05	0.000429	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK8—atopic dermatitis	3.66e-05	0.000416	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL5—atopic dermatitis	3.64e-05	0.000415	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NGF—atopic dermatitis	3.38e-05	0.000384	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—atopic dermatitis	3.35e-05	0.000382	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNG—atopic dermatitis	3.3e-05	0.000376	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCR5—atopic dermatitis	3.28e-05	0.000374	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—atopic dermatitis	3.19e-05	0.000363	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—atopic dermatitis	2.96e-05	0.000337	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—atopic dermatitis	2.95e-05	0.000335	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—atopic dermatitis	2.94e-05	0.000335	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—atopic dermatitis	2.93e-05	0.000334	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKBIA—atopic dermatitis	2.78e-05	0.000317	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK8—atopic dermatitis	2.7e-05	0.000307	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—atopic dermatitis	2.69e-05	0.000306	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—atopic dermatitis	2.57e-05	0.000292	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK8—atopic dermatitis	2.36e-05	0.000269	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—atopic dermatitis	2.33e-05	0.000266	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—atopic dermatitis	2.16e-05	0.000245	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—atopic dermatitis	1.99e-05	0.000226	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—atopic dermatitis	1.9e-05	0.000216	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK8—atopic dermatitis	1.75e-05	0.000199	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—atopic dermatitis	1.72e-05	0.000196	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—atopic dermatitis	1.59e-05	0.000181	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—atopic dermatitis	1.51e-05	0.000172	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—atopic dermatitis	1.12e-05	0.000127	CbGpPWpGaD
